Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection
Clinical trial NCT01838590 · COMPLETED
Trial details
- NCT number
- NCT01838590
- Sponsor
- Gilead Sciences
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2013-03-01
- Primary completion
- 2014-05-01
- Enrollment
- 103
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.